HBC(SH:603077) Xin Lang Cai Jing·2025-11-07 02:19Core Viewpoint - The stock of Hebang Biotechnology has shown a positive trend with a year-to-date increase of 12.75%, reflecting investor interest and market activity [1][2]. Group 1: Stock Performance - On November 7, Hebang Biotechnology's stock rose by 2.22%, reaching 2.30 CNY per share, with a trading volume of 2.18 billion CNY and a turnover rate of 1.09%, resulting in a total market capitalization of 203.12 billion CNY [1]. - The stock has experienced a 5.50% increase over the last five trading days, a 2.22% increase over the last 20 days, and a 22.34% increase over the last 60 days [1]. - Year-to-date, the stock has appeared on the "Dragon and Tiger List" once, with a net buy of 50.22 million CNY on October 9, contributing to a total buy of 229 million CNY, which accounted for 13.21% of total trading volume [1]. Group 2: Company Overview - Hebang Biotechnology, established on August 1, 2002, and listed on July 31, 2012, is located in Leshan, Sichuan Province, and specializes in the manufacturing of pesticides, fine chemicals, and various glass products [2]. - The company's revenue composition includes 85.89% from chemical products, 17.61% from photovoltaic glass and other products, 6.74% from mineral products, and 5.02% from other businesses [2]. - As of September 30, 2025, the company reported a revenue of 5.927 billion CNY, a year-on-year decrease of 13.02%, and a net profit attributable to shareholders of 93.11 million CNY, down 57.93% year-on-year [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period, with an average of 44,939 shares held per shareholder, an increase of 2.03% [2]. - The top ten circulating shareholders include new entrants such as Penghua CSI Sub-Segment Chemical Industry Theme ETF and Everbright Prudential Credit Enhanced Bond A, indicating a shift in institutional holdings [3].